Department of Endoscope, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
Adv Ther. 2024 Oct;41(10):3792-3806. doi: 10.1007/s12325-024-02949-z. Epub 2024 Aug 29.
INTRODUCTION: Concomitant gallbladder and common bile duct (CBD) stones, known as cholecystocholedocholithiasis, are clinically prevalent. There is currently no consensus on sequential versus simultaneous management approaches, and, if simultaneous, which approach to adopt. This meta-analysis evaluates the safety and efficacy of one-stage laparoscopic cholecystectomy (LC) with intraoperative endoscopic retrograde cholangiopancreatography (ERCP) versus two-stage ERCP followed by LC for treating concomitant gallbladder and CBD stones. METHODS: A comprehensive literature search was conducted in five databases, PubMed, Embase, Web of Science, VIP, and Wanfang, for all randomized controlled trials (RCTs), cohort and retrospective studies published up to February 2024. Data extraction was performed independently by two reviewers. The primary outcomes were CBD stone clearance rate and postoperative complications morbidity. Secondary outcomes included conversion to other procedures and length of hospital stay. Statistical analyses were performed using R (v.4.3.2) with weighted mean differences and odds ratios (ORs) calculated for continuous and dichotomous variables, respectively, with 95% confidence intervals (CIs). RESULTS: A total of 17 studies involving 2120 patients have been included, with 898 patients receiving single-stage and 1222 patients undergoing two-stage treatment. Of these studies, 9 were RCTs and 8 were retrospective cohort study. The one-stage group demonstrated superior outcomes in terms of CBD stone clearance (OR = 2.07, p = 0.0004), overall morbidity (OR = 0.35, p < 0.0001), post-operative pancreatitis (OR = 0.49, p = 0.006), conversion to other procedures (OR = 0.38, p = 0.0006), and length of hospital stay (MD = - 2.6456, 95% CI - 3.5776; - 1.7136, p < 0.0001). No significant differences were observed in post-operative cholangitis (OR = 0.44, p = 0.12), post-operative bleeding (OR = 0.76, p = 0.47), or bile leakage (OR = 1.28, p = 0.54). CONCLUSION: For patients with concomitant gallbladder and CBD stones, the one-stage approach combining ERCP and LC appears safer and more effective, with advantages including higher stone clearance rates, reduced postoperative complications (particularly pancreatitis), shorter hospital stays, fewer residual stones, and decreased need for additional procedures. However, additional high-quality clinical trials are needed to establish the optimal treatment approach for various patient scenarios.
介绍:胆囊和胆总管(CBD)结石并存,即胆石性胆石症,临床上较为常见。目前对于序贯或同期处理方法尚无共识,如果同期处理,哪种方法更优也没有定论。本荟萃分析评估了一期腹腔镜胆囊切除术(LC)联合术中内镜逆行胰胆管造影术(ERCP)与二期 ERCP 后行 LC 治疗胆囊和 CBD 结石并存的安全性和疗效。
方法:对 5 个数据库(PubMed、Embase、Web of Science、VIP 和万方)进行了全面的文献检索,检索时间截至 2024 年 2 月,纳入所有随机对照试验(RCT)、队列和回顾性研究。由两位评审员独立进行数据提取。主要结局是 CBD 结石清除率和术后并发症发病率。次要结局包括转为其他手术和住院时间。使用 R(v.4.3.2)进行统计分析,对连续和二分类变量分别计算加权均数差和比值比(OR),置信区间(CI)为 95%。
结果:共纳入 17 项研究,涉及 2120 例患者,其中 898 例接受一期治疗,1222 例接受二期治疗。这些研究中,9 项为 RCT,8 项为回顾性队列研究。一期组在 CBD 结石清除率(OR=2.07,p=0.0004)、总发病率(OR=0.35,p<0.0001)、术后胰腺炎(OR=0.49,p=0.006)、转为其他手术(OR=0.38,p=0.0006)和住院时间(MD=-2.6456,95%CI-3.5776;-1.7136,p<0.0001)方面表现出更好的结果。术后胆管炎(OR=0.44,p=0.12)、术后出血(OR=0.76,p=0.47)或胆漏(OR=1.28,p=0.54)发生率无显著差异。
结论:对于胆囊和 CBD 结石并存的患者,联合 ERCP 和 LC 的一期治疗方法更安全、更有效,其优势包括结石清除率更高、术后并发症(特别是胰腺炎)减少、住院时间缩短、残留结石更少、需要额外手术的可能性降低。然而,还需要更多高质量的临床试验来确定各种患者情况下的最佳治疗方法。
Cochrane Database Syst Rev. 2013-9-3
Cochrane Database Syst Rev. 2013-12-12
Front Med (Lausanne). 2025-4-15
World J Gastroenterol. 2021-7-28